Clinical usefulness and safety in the early phase after a newly designed rotating-platform total knee arthroplasty: A prospective multicentre cohort study with a 2-year follow up

Background: This study aimed to assess the clinical results and safety of a newly designed rotating-platform posterior-stabilised total knee arthroplasty (TKA) in the early postoper-ative phase, within 2 years of follow up. Methods: This prospective, multicentre cohort study included 100 consecutive patients who underwent rotating-platform posterior-stabilised (PS) TKA (Vanguard PSRP). After excluding dropouts, 93 patients were analysed. The objective Knee Society Score (KSS)-2011, subjective KSS-2011, knee range of motion, EuroQol 5 Dimension index, complica-tions, and survival rates were assessed before TKA and at 6 months, 1 year, and 2 years postoperatively. The scores at each time-point were compared, and the survival rate was assessed with revision as the endpoint. To demonstrate non-inferiority, the clinical out-comes of patients who underwent rotating-platform PS TKA were compared with those collected retrospectively from 50 patients who underwent fixed-PS TKA (Vanguard PS), defined as the control group. Results: All clinical outcomes at the final follow up significantly improved compared with their preoperative values (P < 0.001). The objective KSS-2011 was 90.0 +/- 8.2 points, subjec-tive KSS-2011 satisfaction was 30.7 +/- 8.6 points, expectation was 10.4 +/- 2.1 points, and functional activity was 74.0 +/- 18.5 points at 2 years postoperatively. Complications included knee dislocation in one patient and surgical site infection in one patient. The sur-vival rate was 99% at 2 years postoperatively. Clinical outcomes, complications, and sur-vival rates of newly designed TKA were not statistically different compared with the control group. Conclusion: The newly designed rotating-platform PS TKA showed good clinical results and suitable safety during the early postoperative phase in this prospective multicentre cohort study. (c) 2022 Elsevier B.V. All rights reserved.